Who founded Hunterian Medicine?

Hunterian Medicine was founded by Dr. Vinod Jaskula-Ranga.

How much funding has Hunterian Medicine raised?

Hunterian Medicine has disclosed $4.6M raised across 1 round.

Where is Hunterian Medicine headquartered?

Hunterian Medicine is headquartered in Baltimore, US.

Hunterian Medicine

Baltimore, US · Delaware LLC

Hunterian Medicine develops a CRISPR delivery technology using adeno-associated viruses to enable in vivo gene editing for treating genetic diseases. The company targets rare genetic disorders including cystic fibrosis, muscular dystrophy, and ALS, where existing treatments remain unavailable for the vast majority of cases.

AI & Machine Learning Biotech Deep Tech Medical Devices

Founders & leadership

Dr. Vinod Jaskula-RangaFounder, President and CEO

Reported raises · per SEC filings

Form D private placements

$4.6M disclosed across 1 round · 2016

▶$4.6MraisedSep 2024 · 26 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Vinod Jaskula-RangaExecutive Officer, Director

Amount sold: $4.6M
Minimum investment: $50K
First sale: Sep 2016
Incorporated: Limited Liability Company, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 4

by search overlap

Ascidian Therapeutics7 shared keywordsAscidian Therapeutics is a biotechnology company developing RNA-based therapeutics, with a clinical focus that includes ophthalmology and inherited retinal diseases.

Generian Pharmaceuticals5 shared keywordsGenerian Pharmaceuticals is a preclinical biotechnology company developing orally available small molecule therapeutics for diseases with high unmet need, particularly conditions currently treated by biologics. It targets age-related diseases including metabolic disorders, neurodegeneration, and inflammation.

Lyterian Therapeutics4 shared keywordsLyterian Therapeutics develops pharmaceutical treatments by leveraging protein homeostatic mechanisms to target genetically-validated disease drivers. The company focuses on transformative medicines for patients across multiple disease areas.

Viridian Therapeutics3 shared keywordsViridian Therapeutics develops treatments for thyroid eye disease, a rare autoimmune condition affecting the eyes and orbit. The company focuses on clinical development and patient support programs in the biotech sector.

Companies competing with Hunterian Medicine for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase I	2023	$350K
National Institutes of Health (NIH)National Institutes of Health	Phase I	2022	$320K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Hunterian Medicine do?: Hunterian Medicine develops a CRISPR delivery technology using adeno-associated viruses to enable in vivo gene editing for treating genetic diseases. The company targets rare genetic disorders including cystic fibrosis, muscular dystrophy, and ALS, where existing treatments remain unavailable for the vast majority of cases.
Who founded Hunterian Medicine?: Hunterian Medicine was founded by Dr. Vinod Jaskula-Ranga.
How much funding has Hunterian Medicine raised?: Hunterian Medicine has disclosed $4.6M raised across 1 round.
Where is Hunterian Medicine headquartered?: Hunterian Medicine is headquartered in Baltimore, US.